NCT03849495Unknown1 期
A Randomized, Open-label, Single Dose, Two-way Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of CKD-370 With D745 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- AUClast of Empagliflozin
研究概览
简要总结
A randomized, open-label, single dose, two-way crossover study to compare the pharmacokinetics and safety/tolerability of CKD-370 with D745 in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults aged 19 to 55 years
- •Females who are not pregnant or breastfeeding or who have surgical infertility
- •Signed informed consent form
- •Other inclusion criteria, as defined in the protocol
排除标准
- •History of clinically significant hepatic, renal, nervous, immune, respiratory, digestive, urinary, endocrine, hemato-oncology, cardiovascular systemic disease or psychosis disorder
- •Clinical laboratory test values are outside the accepted normal range at Screening
- •aspartate aminotransferase(AST), alanine aminotransferase(ALT) > 1.5 times the upper limit of the normal range
- •Total Bilirubin > 1.5 times the upper limit of the normal range
- •creatine phosphokinase(CPK) > 1.5 times the upper limit of the normal range
- •estimated Glomerular Filtration Rate(eGFR, MDRD* formula) < 60 mL/min/1.73m2 (*MDRD: Modification of Diet in Renal Disease)
- •Positive reaction on following tests: Hepatitis B, Hepatitis C, human immunodeficiency virus(HIV) and syphilis
- •systolic blood pressure(SBP) ≥ 150 mmHg or < 90 mmHg, diastolic blood pressure(DBP) > 100 mmHg or < 50 mmHg
- •Current smokers or those who cannot quit smoking during the period from 90 days before the first IP dosing to the last discharge.
- •Subject who drink excessive caffeine or alcohol continuously and who cannot discontinue caffeine or alcohol intake during the period from 3 days before the first IP dosing to the last discharge.
- •Participated in a clinical trial within 90 days prior to first IP dosing
- •Not eligible to participate for the study at the discretion of Investigator
- •Other exclusive inclusion criteria, as defined in the protocol
研究组 & 干预措施
Group A
Experimental
- Period 1: D745
- Period 2: CKD-370
干预措施: CKD-370 (Drug)
Group A
Experimental
- Period 1: D745
- Period 2: CKD-370
干预措施: D745 (Drug)
Group B
Experimental
- Period 1: CKD-370
- Period 2: D745
干预措施: CKD-370 (Drug)
Group B
Experimental
- Period 1: CKD-370
- Period 2: D745
干预措施: D745 (Drug)
结局指标
主要结局
AUClast of Empagliflozin
时间窗: 0 hour ~ 48 hour after drug administration
Area under the plasma concentration-time curve to last concentration of Empagliflozin
Cmax of Empagliflozin
时间窗: 0 hour ~ 48 hour after drug administration
Maximum plasma concentration of Empagliflozin
次要结局
- Tmax of Empagliflozin(0 hour ~ 48 hour after drug administration)
- AUCinf of Empagliflozin(0 hour ~ 48 hour after drug administration)
- T1/2 of Empagliflozin(0 hour ~ 48 hour after drug administration)
- CL/F of Empagliflozin(0 hour ~ 48 hour after drug administration)
- Vd/F of Empagliflozin(0 hour ~ 48 hour after drug administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy SubjectsHealth, SubjectiveNCT04087525Hanmi Pharmaceutical Company Limited31
已完成
1 期
The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male VolunteersDiabetesHyperlipidemiaNCT02982798Jeil Pharmaceutical Co., Ltd.40
已完成
1 期
The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers.HyperlipidemiasDiabetesNCT03690778Jeil Pharmaceutical Co., Ltd.42
Unknown
1 期
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered AloneHealthyNCT02670018LG Life Sciences25
已完成
1 期
The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy VolunteersOveractive Bladder(OAB)NCT04914221Jeil Pharmaceutical Co., Ltd.42